Economic impact of medication non-adherence by disease groups: a systematic review
Top Cited Papers
Open Access
- 21 January 2018
- Vol. 8 (1), e016982
- https://doi.org/10.1136/bmjopen-2017-016982
Abstract
ObjectiveTo determine the economic impact of medication non-adherence across multiple disease groups.DesignSystematic review.Evidence reviewA comprehensive literature search was conducted in PubMed and Scopus in September 2017. Studies quantifying the cost of medication non-adherence in relation to economic impact were included. Relevant information was extracted and quality assessed using the Drummond checklist.ResultsSeventy-nine individual studies assessing the cost of medication non-adherence across 14 disease groups were included. Wide-scoping cost variations were reported, with lower levels of adherence generally associated with higher total costs. The annual adjusted disease-specific economic cost of non-adherence per person ranged from $949 to $44 190 (in 2015 US$). Costs attributed to ‘all causes’ non-adherence ranged from $5271 to $52 341. Medication possession ratio was the metric most used to calculate patient adherence, with varying cut-off points defining non-adherence. The main indicators used to measure the cost of non-adherence were total cost or total healthcare cost (83% of studies), pharmacy costs (70%), inpatient costs (46%), outpatient costs (50%), emergency department visit costs (27%), medical costs (29%) and hospitalisation costs (18%). Drummond quality assessment yielded 10 studies of high quality with all studies performing partial economic evaluations to varying extents.ConclusionMedication non-adherence places a significant cost burden on healthcare systems. Current research assessing the economic impact of medication non-adherence is limited and of varying quality, failing to provide adaptable data to influence health policy. The correlation between increased non-adherence and higher disease prevalence should be used to inform policymakers to help circumvent avoidable costs to the healthcare system. Differences in methods make the comparison among studies challenging and an accurate estimation of true magnitude of the cost impossible. Standardisation of the metric measures used to estimate medication non-adherence and development of a streamlined approach to quantify costs is required.PROSPERO registration numberCRD42015027338.Keywords
This publication has 93 references indexed in Scilit:
- Association of teriparatide adherence and persistence with clinical and economic outcomes in Medicare Part D recipients: a retrospective cohort studyBMC Musculoskeletal Disorders, 2013
- Association between oral 5-ASA adherence and health care utilization and costs among patients with active ulcerative colitisBMC Gastroenterology, 2012
- Greater Adherence To Diabetes Drugs Is Linked To Less Hospital Use And Could Save Nearly $5 Billion AnnuallyHealth Affairs, 2012
- Adherence to Statins, Subsequent Healthcare Costs, and Cardiovascular HospitalizationsThe American Journal of Cardiology, 2011
- The Association between Adherence to Levodopa/Carbidopa/Entacapone Therapy and Healthcare Utilization and Costs among Patients with Parkinsonʼs DiseaseCNS Drugs, 2011
- Medication Adherence and Healthcare Costs among Fibromyalgia Patients Treated with DuloxetinePain Practice, 2010
- A retrospective cohort study of economic outcomes and adherence to monotherapy with metformin, pioglitazone, or a sulfonylurea among patients with type 2 diabetes mellitus in the united states from 2003 to 2005Clinical Therapeutics, 2010
- The Relationship of Antipsychotic Medication Class and Adherence with Treatment Outcomes and Costs for Florida Medicaid Beneficiaries with SchizophreniaAdministration and Policy in Mental Health and Mental Health Services Research, 2007
- Treatment Interruptions and Non-Adherence with Imatinib and Associated Healthcare CostsPharmacoEconomics, 2007
- Association of Medication Adherence with Workplace Productivity and Health-Related Quality of Life in Patients with AsthmaJournal of Asthma, 2006